POPULARITY
Categories
2,432 episodes with 3d imaging
1,003 episodes with 3d imaging
238 episodes with 3d imaging
66 episodes with 3d imaging
31 episodes with 3d imaging
3 episodes with 3d imaging
2 episodes with 3d imaging
2 episodes with 3d imaging
2 episodes with 3d imaging
A project called Antscan has generated high resolution images of thousands of ants, representing over 700 species. To make it happen, researchers brought preserved ants from collections around the world to a particle accelerator in Germany. There, a powerful synchrotron X-ray source combined with a vial-swapping robot allowed the researchers to build a collection of 3D ant images, inside and out. Each voxel (like a 3D pixel) has a resolution of 1.22 micrometers—enough to see the tiny hairs on ant bodies, and distinguish individual muscle fibers. Antscan researcher Julian Katzke joins us to describe the background of the project, and how the images could be used for science and art. Check out Antscan images at our website. Guest: Dr. Julian Katzke is a postdoc at the Smithsonian National Museum of Natural History. He worked on the AntScan project while a PhD student at the Okinawa Institute of Science and Technology. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
03/01/2026 | March 2026 Quiz
2/3/2026 | Musculoskeletal
02/01/2026 | February 2026 Quiz
Research Using AI and 3D Imaging Unveils Unique Terrain of Individual Tongue SurfacesBy Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/research-using-ai-and-3d-imaging-unveils-unique-terrain-of-individual-tongue-surfaces/Need CE? Start earning CE credits today at https://rdh.tv/ce Get daily dental hygiene articles at https://www.todaysrdh.com Follow Today's RDH on Facebook: https://www.facebook.com/TodaysRDH/Follow Kara RDH on Facebook: https://www.facebook.com/DentalHygieneKaraRDH/Follow Kara RDH on Instagram: https://www.instagram.com/kara_rdh/
01/01/2026 | January 2026 Quiz
12/01/2025 | December 2025 Quiz
12/1/2025 | Musculoskeletal
11/01/2025 | November 2025 Quiz
10/01/2025 | October 2025 Quiz
Dr. Peter Altman, President and CEO of BioCardia, is focused on treating ischemic heart failure and chronic myocardial ischemia using autologous cells from the patient's bone marrow. The company has developed a cost-effective model that utilizes a pre-procedure diagnostic to select the optimal patients for this point-of-care system, which processes their cells in a single procedure. A key technology is the Helix catheter system, which enables minimally invasive delivery of cells into the heart, aided by the Heart3D Fusion imaging platform that provides a 3D map for precise cell delivery. Peter explains, "BioCardia's focus is on ischemic etiology of heart disease. This is heart disease that results from poor perfusion, typically following, for example, a heart attack, which is an ischemic disease. And the two diseases we're working on are ischemic heart failure, which is often characterized by a large dilated heart. And in the second is chronic myocardial ischemia, which is characterized by what's called refractory angina or chest pain that actually can be incredibly severe. And so are our focus areas. And we're advancing cell therapies that have been shown to inherently improve the cells we're looking at, which are cells from the bone marrow space, the mononuclear cells that contain the CD34 and CD133 cell populations. They're actually involved in forming new microvasculature and supply." "What we've done is come at it from a different perspective. Instead of selecting the cells and then manufacturing in a remote facility, we have a pre-procedure diagnostic that enables us to select the patients who have appropriate cells and then process them with a point-of-care cell processing platform, which involves just a simple disposable cartridge. And then we can treat these patients in a standard interventional cardiology setting at relatively low cost compared to all cell therapies." #BioCardia #HeartDisease #AutologousCellTherapy #CellTherapy #3DImaging #Heart3DFusion #CardiAMP biocardia.com Download the transcript here
Dr. Peter Altman, President and CEO of BioCardia, is focused on treating ischemic heart failure and chronic myocardial ischemia using autologous cells from the patient's bone marrow. The company has developed a cost-effective model that utilizes a pre-procedure diagnostic to select the optimal patients for this point-of-care system, which processes their cells in a single procedure. A key technology is the Helix catheter system, which enables minimally invasive delivery of cells into the heart, aided by the Heart3D Fusion imaging platform that provides a 3D map for precise cell delivery. Peter explains, "BioCardia's focus is on ischemic etiology of heart disease. This is heart disease that results from poor perfusion, typically following, for example, a heart attack, which is an ischemic disease. And the two diseases we're working on are ischemic heart failure, which is often characterized by a large dilated heart. And in the second is chronic myocardial ischemia, which is characterized by what's called refractory angina or chest pain that actually can be incredibly severe. And so are our focus areas. And we're advancing cell therapies that have been shown to inherently improve the cells we're looking at, which are cells from the bone marrow space, the mononuclear cells that contain the CD34 and CD133 cell populations. They're actually involved in forming new microvasculature and supply." "What we've done is come at it from a different perspective. Instead of selecting the cells and then manufacturing in a remote facility, we have a pre-procedure diagnostic that enables us to select the patients who have appropriate cells and then process them with a point-of-care cell processing platform, which involves just a simple disposable cartridge. And then we can treat these patients in a standard interventional cardiology setting at relatively low cost compared to all cell therapies." #BioCardia #HeartDisease #AutologousCellTherapy #CellTherapy #3DImaging #Heart3DFusion #CardiAMP biocardia.com Listen to the podcast here
© 2020-2026 Ivy Podcast Discovery LLC
